Medpace Holdings Inc. (MEDP)
3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.
Medpace: Cancellations Are Normalizing
Medpace Holdings demonstrates strong Q2 2026 net new business awards, with a 1.13x net book-to-bill and $3.0B backlog. Oncology bookings are robust, while cardiometabolic awards have declined; management expects mix normalization over the next year. Guidance is lifted on improved RFP trends, biotech funding breadth, and moderated cancellations, supporting growth momentum into 2027.
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcript
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcript
Medpace Q2 Earnings Call Highlights
Medpace NASDAQ: MEDP reported double-digit growth in second-quarter revenue and earnings, while management described the business environment as strong and said lower cancellations helped drive record net bookings.
Medpace (MEDP) Beats Q2 Earnings and Revenue Estimates
Medpace (MEDP) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.1 per share a year ago.
Why Medpace (MEDP) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Medpace (MEDP) Dipped More Than Broader Market Today
Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day.
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
Medpace Stock Outlook Turns on Backlog Quality and Cancellations
MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, Medpace (MEDP) stood at $543.57, denoting a +2.64% move from the preceding trading day.
Medpace (MEDP) Advances While Market Declines: Some Information for Investors
Medpace (MEDP) reached $519.96 at the closing of the latest trading day, reflecting a +1.4% change compared to its last close.
